Drugs for inflammatory conditions drove nearly half of spending in commercial plans last year, a new report shows. Express Scripts released its annual Drug Trend Report, which analyzes costs and ...

44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

The federal government has backed off a proposal that would have let Medicare Part D prescription drug plans deny coverage for therapies in six "protected" classes of drugs, including those for cancer ...

Credit: Getty Images In an unexpected finding, phosphodiesterase inhibitors and sympathomimetics with α- and β-effect were strongly associated with higher AKI risk in this analysis. High AKI risk was ...

Drug classes such as alpha-1 blockers, atypical antipsychotics, and tricyclic antidepressants were associated with an increased incidence of intraoperative floppy iris syndrome (IFIS), with imipramine ...

The vision of precision oncology entails a shift toward (semi)automated, data-driven workflows that guide treatment on the basis of an individual patient's clinical and molecular profile and leverage ...

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. If you look at the last 20 years as a ...

President Trump signed an order to reschedule marijuana to a lower drug classification, one of the most significant changes ...

Please provide your email address to receive an email when new articles are posted on . The thiazolidinedione pioglitazone and GLP-1 receptor agonists are the only two diabetes drugs proved to ...

Two new classes of HIV drugs are poised to hit the market in 2007, signalling what many say is a watershed in HIV treatment, second only to the introduction of cocktail therapy more than a decade ago.

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...